Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

WALTHAM, Mass., Nov. 11, 2025 — Clinical‑stage global biopharmaceutical company Zenas BioPharma, Inc. (Nasdaq: ZBIO) announced today that it will present at two major upcoming investor conferences — the Jefferies Global Healthcare Conference in London on November 18 at 11:00 a.m. GMT, and the 8th Annual Evercore Healthcare Conference on December 3 at 7:55 a.m. ET. The company’s management team will deliver live webcasts of their presentations, with archived replay access via the “Events & Presentations” section of the Zenas website. Zenas is focused on developing and commercialising transformative therapies for patients living with autoimmune diseases. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb on B cells, designed to suppress pathogenic activity without depleting cells. Its other late‑stage candidate, orelabrutinib, is a CNS‑penetrant oral BTK inhibitor aimed at targeting pathogenic B cells and microglia in multiple sclerosis. The company also has earlier‑stage programs including an oral IL‑17AA/AF inhibitor and a brain‑penetrant TYK2 inhibitor. #biotech #autoimmunetherapy #investorconference #ZenasBioPharma #SlimScan #GrowthStocks #CANSLIM